Mike O'Neill's "Investor Relations Questions" Archive
Welcome to a new feature here at BiotechDueDIligence. Fellow biotech enthusiast Mike O'Neill (be sure to follow him on Twitter @MikeOinSATX) has graciously agreed to archive his biotech investor relations (IR) questions and answers here on the website. Mike starts his due diligence on any biotech stock by asking their IR department the same five questions:
Mike shares each and every response from biotech investor relations reps on Twitter and we will also post them here at BiotechDueDiligence. In some cases the answers are the result of Mike's own research instead. Use the index on this page to access the latest information from a wide range of biotech companies.
- When was the last time the company raised money (diluted) through a stock offering?
- How much cash (not cash equivalents) does the company have?
- What and approximately when is the company's next know catalyst?
- What is the company's quarterly burn rate?
- Does the company have an existing line of credit and if so how much can they draw on it?
Mike shares each and every response from biotech investor relations reps on Twitter and we will also post them here at BiotechDueDiligence. In some cases the answers are the result of Mike's own research instead. Use the index on this page to access the latest information from a wide range of biotech companies.
Investor information updated August 2013
INSV InSite Vision
ONCY Oncolytics Biotech
PTIE Pain Therapeutics
RIGL Rigel Pharmaceuticals
SNTI Senesco Technologies
ONCY Oncolytics Biotech
PTIE Pain Therapeutics
RIGL Rigel Pharmaceuticals
SNTI Senesco Technologies
Investor information updated June-July 2013
ACHN Achillion Pharmaceuticals
BTX BioTime Inc
DRIO Labstyle Innovations
ENZ Enzo Biochem
IDIX Idenix Pharmaceuticals
IGXT IntelGenx
PSDV pSivida Corp
TELK Telik IncVICL Vical Incorporated
BTX BioTime Inc
DRIO Labstyle Innovations
ENZ Enzo Biochem
IDIX Idenix Pharmaceuticals
IGXT IntelGenx
PSDV pSivida Corp
TELK Telik IncVICL Vical Incorporated